Of note, the mutation frequency of the entire cohort closely matched the frequency detected in relapsed tumors of the sub-cohort of patients for whom paired samples from diagnosis and relapse were available (n = 101), suggesting that ALK mutations may occur de novo in 7% of relapsed or progressive neuroblastoma. The gene discussed is ALK; the disease is neuroblastoma.